LIXTE raises $6.5M, adds new CEO/board members, regains Nasdaq compliance

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Completed two financings raising $6.5M gross ($5M private placement + $1.5M registered direct); proceeds for working capital.
Regained compliance for continued listing on Nasdaq Capital Market.
Geordan Pursglove appointed Chairman and CEO in June 2025; Bas van der Baan becomes President and CSO.
Nature published findings validating LB-100 mechanism; new pre-clinical study with Netherlands Cancer Institute.
Jason Sawyer and Michael Holloway joined Board as independent directors; Forman and Yen moved to Scientific Advisory Committee.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.